The efficacy of botulinum toxin in refractory overactive bladder | ||||
| Journal of Current Medical Research and Practice | ||||
| Volume 6, Issue 4, October 2021, Page 331-335 PDF (326.8 K) | ||||
| DOI: 10.4103/jcmrp.jcmrp_13_21 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed Farahat; Ahmed El-Azab; Hassan A. Abolella | ||||
| Abstract | ||||
| Aim and objectives The objective of this study was to evaluate the efficacy and safety of botulinum toxin A (BTX-A) injection in patients with refractory overactive bladder (OAB). Patients and methods The study was done in Assiut Urology Hospital, Assiut University, from June 2017 to January 2020. The study included 22 patients (15 patients with idiopathic OAB and seven patients with neurogenic OAB). Botox was injected intradetrusor (200 U of Botox for neurogenic OAB and 100 U of Botox for idiopathic OAB). Patients were followed up for 1 year. Results The success rate after 3 months reached 81.8% (63.6% became completely dry and 18.2% had improved symptoms) with treatment failed in 18.2%. The improvement continues for 6 months postoperatively and reached 60% (40.9% became completely dry and 18.2% had improved symptoms), and treatment failed in 40.9%. At 6-month interval, the voiding diary parameters showed significant improvement in the number of voids ( = 0.000) and the number of incontinent episodes ( = 0.000). Regarding the adverse effects, urinary tract infection occurred in two (9%) patients after intervention, and urinary retention occurred in two (9%) patients. Conclusion BTX-A is an excellent and successful option for patients with refractory OAB. BTX-A is a minimally invasive option for refractory OAB. Complications are uncommon with sustained effect up to 6–12 months. | ||||
| Keywords | ||||
| Botulinum toxin A; INCONTINENCE; Overactive bladder | ||||
|
Statistics Article View: 46 PDF Download: 36 |
||||
